Leadership
-
eranicle via Getty Images
Q&AHow AZ’s respiratory wins are ramping up for a bigger prize in COPD
As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up for past stumbles in COPD.
By Michael Gibney • Oct. 29, 2024 -
Permission granted by Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Biotech Pathfinders
Leaders solving biology's toughest puzzles and driving innovation forward.
By Michael Gibney • Oct. 23, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
George Clerk via Getty Images
With activist investment rising, Pfizer’s battle with Starboard reflects the industry’s post-pandemic tumble
Pfizer’s proxy battle with Starboard has gotten messy. It’s the latest in a series of activist investor campaigns that have been on the rise in recent years.
By Michael Gibney • Oct. 22, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Patient Champions
Leaders advancing health advocacy, DEI initiatives and better medicine access for patients.
By Meagan Parrish • Oct. 22, 2024 -
PharmaVoice/PharmaVoice
PharmaVoice 1002024 PharmaVoice 100s: Cardiometabolic All-Stars
Leaders tackling long-standing health needs with new solutions.
By Amy Baxter • Oct. 18, 2024 -
Permission granted by Parexel
Clinical staff that feel like ‘tech support’ — and other issues a CRO exec contends with
From tech-related challenges to an ongoing staffing crunch, Parexel’s CEO explains what the clinical trials industry is up against.
By Meagan Parrish • Oct. 18, 2024 -
Christopher Furlong via Getty Images
Want to launch a blockbuster? An AstraZeneca exec breaks it down.
Even drugs with “blockbuster potential” often fall short of expectations. Here’s what can help a new medication pass the $1 billion mark.
By Alexandra Pecci • Oct. 16, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Trailblazers
Industry leaders charting new paths in science and business.
By Meagan Parrish • Oct. 16, 2024 -
Motortion via Getty Images
Regeneron takes the long-haul approach to oncology, stumbles and all
Although Regeneron has been playing catch-up in the oncology field for years, a pipeline built on next-wave promises could push the boundaries.
By Michael Gibney • Oct. 10, 2024 -
Permission granted by Biocom
Q&ACalifornia is a life sciences leader. Joe Panetta has been one of its most vocal advocates.
The president and CEO of Biocom California discusses the state’s strengths and weaknesses, current and emerging hubs, and the industry’s future.
By Alexandra Pecci • Oct. 1, 2024 -
Stock via Getty Images
Behind the rise of BMS’ Cobenfy, the first new schizophrenia drug in decades
The FDA OK for KarXT, now known as Cobenfy, demonstrates Bristol Myers Squibb’s dealmaking prowess and marks a turning point for a new generation of treatments.
By Kelly Bilodeau • Sept. 26, 2024 -
Permission granted by Roivant Sciences
Q&ARoivant’s magic trick: Finding the ‘weird-shaped’ pieces around Big Pharma’s cookie cutters
Roivant CEO Matt Gline leads the company on a unique path by placing bets on misfit drugs and technologies — and it’s working.
By Michael Gibney • Sept. 26, 2024 -
Permission granted by CRI
Q&A // First 90 DaysWant better cancer treatments? Make biopharma more like Silicon Valley
Alicia Zhou brings startup bona fides to the nonprofit Cancer Research Institute to promote defragmentation of the cancer research effort.
By Michael Gibney • Sept. 24, 2024 -
iStock via Getty Images
At J&J, oncology R&D meets commercial strategy in a quest for new standards of care
The disparate teams of research and commercial at J&J work closely together from the get-go.
By Michael Gibney • Sept. 19, 2024 -
Michael Vi / Getty Images via Getty Images
Q&AHow Lilly’s sustainability goals come face to face with massive growth
Eli Lilly’s head of ESG is maintaining a focus on sustainability even as the company’s expansion plans in weight loss drive a larger footprint and more social scrutiny.
By Michael Gibney • Sept. 12, 2024 -
Permission granted by Merck & Co.
Big Pharma is often media shy. Merck’s chief comms officer is hoping to change that.
Cristal Downing is helping Merck & Co. buck pharma’s zipped-lip status quo and usher in a “new era” of openness, transparency and “overt communication.”
By Alexandra Pecci • Sept. 5, 2024 -
Getty Images via Getty Images
Their Alzheimer’s treatment worked — but shares fell anyway
Cognition Therapeutics touted what the C-suite saw as a promising mid-stage study in Alzheimer’s, but investors read a different story.
By Michael Gibney • Aug. 29, 2024 -
Permission granted by Takeda Pharmaceuticals
Q&A // First 90 DaysWith a new oncology R&D head, Takeda revamps its strategy
The company is using a “three-by-four” approach to sharpen its cancer R&D aims.
By Alexandra Pecci • Aug. 27, 2024 -
Courtesy of BioMarin Pharmaceutical
BioMarin taps Amgen, Roche vets in executive reshuffle
Greg Friberg and James Sabry will take over, respectively, as heads of R&D and business development, less than a year after BioMarin named a new CEO.
By Jacob Bell • Aug. 22, 2024 -
Permission granted by Reed Tuckson
Lessons from COVID: Tuskegee impacts still erode trust in healthcare, but hope shines through
A long-time leader in public health and outreach to people of color, Dr. Reed Tuckson offers the lessons he learned from the COVID pandemic and how pharma can better serve those communities.
By Michael Gibney • Aug. 15, 2024 -
Getty Images via Getty Images
Q&A // Biotech SpotlightA biotech’s difficult journey to bring a new kind of Parkinson’s drug to patients
A series of executive turnovers at Gain Therapeutics this year precedes important early-stage Parkinson’s results that could change how the disease is treated.
By Michael Gibney • Aug. 13, 2024 -
Spencer Platt via Getty Images
Pharma execs react to final drug price negotiations with Medicare
Here’s what the leaders of the companies with the 10 drugs in the first wave of price negotiations with Medicare said about how the new prices will impact their portfolio.
By Amy Baxter • Aug. 9, 2024 -
Permission granted by University of Pennsylvania
Jim Wilson, prominent gene therapy researcher, to depart UPenn
Wilson, who founded UPenn’s gene therapy program three decades ago, will step down to start two new spinouts, Gemma Bio and Franklin Biolabs.
By Ned Pagliarulo • Aug. 5, 2024 -
Stock via Getty Images
OpinionWhat pharma has learned from AI
As AI tools move from hype to a daily reality at pharma companies, here are the insights users are gaining.
By Meagan Parrish • Aug. 2, 2024 -
Stock via Getty Images
Read to lead: 6 books pharma execs swear by
From an epic, alternative reality fantasy to a ‘biography of cancer,’ these six reads have stuck with pharma execs as they navigate how to lead.
By Alexandra Pecci • Aug. 1, 2024
